Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48

Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48

Background Immune checkpoint inhibitors have shown limited response rates in bladder cancer. RC48-antibody-drug conjugate (ADC) shows potential for combination with immune checkpoint inhibitors. This study aimed to elucidate RC48-ADC’s mechanism in sensitizing tumors to immunotherapy and identify op...

Full description

Saved in:
Bibliographic Details
Main Authors: Xin Gao, Chunyu Zhang, Jinbo Chen, Zhi Liu, Jiao Hu, Xiongbing Zu, Jiatong Xiao, Jinhui Liu, Zhenyu Nie, Zhenglin Yi, Haisu Liang, Jinliang Huang, Zhiyong Cai, Luzhe Yan, Bingquan Wu, Zefu Liu
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/8/e011881.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/8/e011881.full

Similar Items